Breaking News, Collaborations & Alliances

OliX, Lilly Enter Global Licensing Agreement for Cardiometabolic Indications

To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

South Korea-based OliX Pharmaceuticals, Inc., a developer of RNAi therapeutics, entered a global licensing agreement with Eli Lilly and Co. focused on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications. OliX will receive an initial payment from Lilly to complete the Phase 1 clinical trial, currently underway in Australia. OLX75016 derives from a target discovered th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters